SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50206-014002
	Serial No.	10/654,763
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Nicholas P. Barker et al.
	Filing Date	September 3, 2003
	Group	1616
(37 C.F.R. § 1.98(b))	IDS Filed	June 23, 2004
	Customer No.	21559

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
BDH	4,647,454	03/03/87	Cymbalista			
	5,349,001	09/20/94	Greenwald et al.			
	5,359,030	10/25/94	Ekwuribe			
	5,382,657	01/17/95	Karasiewicz et al.			
	5,446,090	08/29/95	Harris			
	6,296,844	10/02/01	Takahashi			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
BDH	WO 98/16255 A2	04/23/98	PCT			
	WO 00/66137 A1	11/9/00	PCT			
	WO 02/32414 A2	04/25/02	PCT			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

BDH	Bailon et al., "Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α 2a for the treatment of hepatitis C," *Bioconjugate Chem.* 12:195-202 (2001).
	Burgess et al., "Abnormal surface distribution of the human asialoglycoprotein receptor in cirrhosis," Hepatology 15:702-706 (1992).
	Cutrone et al., "Identification of critical residues in bovine IFNAR-1 responsible for interferon binding," *J. Biol. Chem.* 276:17140-17148 (2001).
	Dotzauer et al., "Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via the asialoglycoprotein receptor," *J. Virology* 74:10950-10957 (2000).

EXAMINER Bruce D. Hess	DATE CONSIDERED 3/9/06

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Attorney Docket No.	50206-014002
	Serial No.	10/654,763
	Applicant	Nicholas P. Barker et al.
	Filing Date	September 3, 2003
	Group	1616
(37 C.F.R. § 1.98(b))	IDS Filed	June 23, 2004
	Customer No.	21559

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
BD/+	Eisenberg et al., "Alaloglycoprotein receptor in human isolated hepatocytes from normal liver and its apparent increase in liver with histological alterations," *J. Hepatol.* 13:305-309 (1991).
	Eto et al., "Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon," *Nature Medicine* 5:577-581 (1999).
	Glue et al. "Pegylated interfereon- α 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data," *Clinical Pharmacology & Therapeutics* 68:556-567 (2000).
	Grace et al., "Structural and biologic characterization of pegylated recombinant IFN- α 2b," *J Interferon Cytokine Res.* 21:1103-1115 (2001).
	Harvey et al., "Gonococcal lipooligosaccharide is a ligand for the asialoglycoprotein receptor on human sperm," *Mol. Microbiol.* 36:1059-1070 (2000).
	Harvey et al., "Receptor-mediated endocytosis of *Neisseria* gonorrhoeae into primary human urethral epithelial cells: The role of the asialoglycoprotein receptor," *Mol. Microbiol* 42:659-672 (2001).
	Hirose et al., "Regulation of asialoglycoprotein receptor expression in proliferative state of hepatocytes," *Biochem. Biophys. Res. Communications* 287:675-681 (2001).
	Karpusas et al., "The crystal structure of human interferon β at 2.2-A resolution," *Proc. Natl. Acad. Sci. USA* 94:11813-11818 (1997).
	Kasama et al., "Pharmacokinetics and biologic activities of human native and asialointerferon- βs," *J. Interferon Cytokine Res.* 15:407-415 (1995).
	Lee et al., "Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin," *J. Biolog. Chem.* 258:199-202 (1983).
	Mizuno et al., "Distributionof asialoglycoprotein receptor in human hepatocellular carcinoma," *Liver* 13:80-85 (1993).
	Monkarsh et al., "Positional isomers of monopegylated interferon α-2a: Isolation, characterization, and biological activity," *Anal. Biochem.* 247:434-440 (1997).
	Nyman et al., "Structural characterisation of N-linked and O-linked oligosaccharided derived from interferon- α 2b and interferon- α14c produced by Sendai-virus-induced human peripheral blood leukocytes," Eur. J. Biochem. 253:485-493 (1998).

EXAMINER	Bruce D. Gitlin	DATE CONSIDERED	3/9/06

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50206-014002
	Serial No.	10/654,763
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Nicholas P. Barker et al.
	Filing Date	September 3, 2003
	Group	1616
(37 C.F.R. § 1.98(b))	IDS Filed	June 23, 2004
	Customer No.	21559

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
BDH	Pepinsky et al., "Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-β-1a with preserved in vitro bioactivity," *J. Pharmacol. Exp. Ther.* 297:1059-1066 (2001).
	Qin et al., "Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice," *Proc. Natl. Acad. Sci. USA* 95:14411-14416 (1998).
	Qin et al., "Human and mouse IFN- β gene therapy exhibits different anti-tumor mechanisms in mouse models," *Mol. Therapy* 4:356-364 (2001).
	Schering-Plough Research Institute, "Toxicologist's Review of Pegylated Interferon-α 2b (PEG-IFN, PEG-INTRON)," December 19, 2000.
	Tada et al., "Systemic IFN-β gene therapy results in long-term survival in mice with established colorectal liver metastases," *J. Clin. Invest.* 108:83-95 (2001).
	Takahashi et al., "Acute hepatitis in rats expressing human hepatitis B virus transgenes," *Proc. Natl. Acad. Sci. USA* 92:1470-1474 (1995).
	Trelber , "Systemic treatment of hepatocellular carcinoma," *Dig. Dis.* 19:311-323 (2001).
	Trere et al., "The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells," *British J. Cancer* 81:404-408 (1999).
	U.S. Food and Drug Administration, Product Approval Information: Peginterferon alfa-2b. May 28, 2002.
	Uwatoku et al., "Asialoglycoprotein receptors on rat dendritic cells: possible roles for binding with kupffer cells and ingesting virus particles," *Arch. Histol. Cytol.* 64:223-232 (2001).
	Wang et al., "Identification of the major positional isomer of pegylated interferon alpha-2b," *Biochem.* 39:10634-10640 (2000).

EXAMINER Bruce D. Hess	DATE CONSIDERED 3/9/06

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.